Naloxone Mini-Grant Program
The Office of Drug Policy (ODP) is pleased to offer its FY19 Naloxone Mini-Grant Program. The purpose of the program is to reduce the incidence of morbidity and mortality related to opioid overdoses in communities in Idaho through the purchase and placement of naloxone, an opioid antagonist used to rapidly reverse the effects of opioid overdoses.
On July 1, 2015, Idaho's law allowing easier access to naloxone went into effect. Since that time, significant progress has been made in educating prescribers and pharmacists about the new law and their roles in it. Many pharmacies are now stocking naloxone and prescribers and pharmacists are becoming more knowledgeable and comfortable recommending and dispensing the medication. The next step is getting this life-saving drug into the hands of those who are in a position to assist a person at risk of experiencing an opioid-related overdose. When equipped, these individuals will be able to administer naloxone and keep an overdose patient alive until they can be transported to an emergency department or distribute naloxone to clients, patients, etc. who are at risk of an overdose, as well as their friends and family.
ODP has received grant funding for the purchase and distribution of naloxone kits to first responders and eligible agencies, prioritizing areas of Idaho with the highest overdose death rates as well as the highest number of overdose deaths.
Agencies eligible under this mini-grant program are:
- First Responders: Law Enforcement, Fire, and EMS
- Substance Use Disorder Treatment and Recovery Support Agencies
- Crisis Centers
- Homeless Shelters
- Hospital Emergency Departments
Agencies may store or have employees carry naloxone with the intent to administer to any individual they encounter who is experiencing an opioid overdose. Agencies may also distribute naloxone to clients, patients, and individuals being released from correctional facilities who are at risk of an overdose, as well as their friends and family.
Each naloxone kit contains 2 doses of 4mg Naloxone Nasal Spray. Funding will be available until September 30, 2019 or until supplies run out. Agencies that receive naloxone through this mini-grant program will be asked to provide brief, online, quarterly reports.